questionText: To ask the Secretary of State for Health and Social Care, what discussions he has had with the MHRA on the potential impact of regulatory reform on the time taken to develop glioblastoma treatments.
answerText: The Medicines and Healthcare Products Regulatory Agency (MHRA) is an executive agency of the Department and regulates medicine, medical devices, and blood components for transfusion in the United Kingdom, with responsibility for ensuring medicines meet ap...
heading: Glioblastoma: Medical Treatments